Last $11.43 USD
Change Today +0.71 / 6.62%
Volume 1.1M
OHRP On Other Exchanges
As of 8:10 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

ohr pharmaceutical inc (OHRP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/17/14 - $20.00
52 Week Low
05/12/14 - $6.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ohr pharmaceutical inc (OHRP) Related Bloomberg News

View More Bloomberg News

ohr pharmaceutical inc (OHRP) Related Businessweek News

No Related Businessweek News Found

ohr pharmaceutical inc (OHRP) Details

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes. The company is evaluating OHR-102 eye drops in various Phase II studies for the treatment of retinal diseases, including wet-AMD, retinal vein occlusion, proliferative diabetic retinopathy, and diabetic macular edema. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as steroid induced glaucoma, allergies, and retinal disease. The company is headquartered in New York, New York.

13 Employees
Last Reported Date: 12/22/14

ohr pharmaceutical inc (OHRP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $219.0K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $177.7K
Compensation as of Fiscal Year 2014.

ohr pharmaceutical inc (OHRP) Key Developments

Ohr Pharmaceutical Announces Additional Positive Anatomic Data from the OHR-102 Impact Study

Ohr Pharmaceutical, Inc. announced the presentation of new data from the IMPACT study interim analysis at the 38th Annual Macula Society Meeting which took place February 25-28th, in Scottsdale, Arizona. The new data show an early regression of subretinal hyper-reflective material (SHRM), an anatomic biomarker for the wet form of age-related macular degeneration (wet-AMD), which is consistent with the early gains in visual acuity previously reported from this study. The IMPACT study is a nine-month Phase II clinical trial evaluating Squalamine Eye Drops (OHR-102) for the treatment of wet-AMD. Previously announced interim data demonstrated that the combination of OHR-102 plus Lucentis® resulted in a meaningful and clinically relevant improvement in visual acuity compared with Lucentis monotherapy. OHR-102 appeared to have a rapid onset of action, with differences between the combination and control arms observed as early as 4 weeks and continuing to increase at week 12. At the end of the study, patients treated with the combination of OHR-102 plus Lucentis were still improving. The dramatic and early vision gains observed are believed to result in part from the regression of SHRM, which is widely considered to be a combination of neovascular tissue, pre-fibrotic material and other sub retinal exudative and inflammatory debris. The new data presented at the Macula Society Meeting showed that, in a masked analysis of spectral domain optical coherence tomography (OCT) images, the reduction in SHRM occurred early in the study, with differences between the treatment and control groups observed by week 4. The early differences between combination therapy and control groups were observed both in the overall treatment population, as well as in the subset of patients with classic-containing choroidal neovascularization (CNV) lesions, where the difference was even greater. Also presented were new data showing that treatment with OHR-102 appears to prevent further development of SHRM. In those patients treated with the OHR-102 plus Lucentis combination, none experienced worsening in SHRM over the 9 months of the study. In contrast, among Lucentis monotherapy patients, 15% of the overall group and 23% of the classic-containing CNV lesion group experienced worsening of SHRM by the end of the study.

Ohr Pharmaceutical, Inc. Appoints Avner Ingerman as Chief Clinical Officer

Ohr Pharmaceutical, Inc. announced the appointment of Avner Ingerman, MD, to the newly created position of Chief Clinical Officer. Dr. Ingerman is an ophthalmologist, with more than 15 years of pharmaceutical industry product development experience. He will be responsible for the management and operation of Ohr's clinical development programs, including the upcoming Phase III trials of OHR-102 in wet-AMD and additional studies evaluating OHR-102 in other retinal indications. Dr. Ingerman's previous roles included serving as Vice President of Ophthalmology at Regeneron Pharmaceuticals.

Ohr Pharmaceutical, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2014

Ohr Pharmaceutical, Inc. reported earnings results for the first quarter ended December 31, 2014. For the first quarter, the company reported a net loss of approximately $4.6 million, or $0.18 per share, compared with $2.0 million, or $0.10 per share, in the first quarter of 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OHRP:US $11.43 USD 0.00

OHRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OHRP.
View Industry Companies

Industry Analysis


Industry Average

Valuation OHRP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 12.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OHR PHARMACEUTICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at